MET and non-small cell lung carcinoma: MET amplification (defined as MET:CEP7 ratio ≥ 2) has been found to correlate with increased clinical response of metastatic gastric cancer to foretinib in a phase II study [78]; whereas MET copy number (positives scored as ≥ four copies in ≥ 40% of cells), to correlate with increased clinical response to tivantinib with erlotinib in advanced NSCLC [79].